Cardiac tumors secondary prevention

Cardiac tumors Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Cardiac Tumors from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Cardiac tumors secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Cardiac tumors secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Cardiac tumors secondary prevention
CDC on Cardiac tumors secondary prevention
Cardiac tumors secondary prevention in the news
Blogs on Cardiac tumors secondary prevention
Directions to Hospitals Treating Cardiac tumors
Risk calculators and risk factors for Cardiac tumors secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Template:Dj

Overview

The secondary prevention can be used in the treatment of cardiac tumors in children to prevent the adverse effects of Anthracyclines. Anthracyclines are commonly used in the treatment of cardiac malignancy in children.

Secondary Prevention

Definition: Secondary prevention focuses on early illness identification and targets persons who appear healthy but have subclinical disease types. The subclinical disease is characterized by pathologic alterations, but lacks overt manifestations that can be diagnosed during a doctor's visit.

Echocardiograph can be used for screening in patients with Tuberous sclerosis and other genetic syndromes and help in secondary prevention.

• The concept of secondary prevention is effective in the chemotherapeutic treatment of cardiac tumors.
  • Most pharmaceutical approaches for long-term tumor survivors exposed to cardiotoxic medications have been adopted from investigations of adults.
  • To avoid the development of silent LVSD to clinical disease, these measures include proactive screening and administration of angiotensin-converting enzyme (ACE) inhibitors and Beta-blockers.